We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Par Receives FDA Approval to Market Generic Zofran ODT
Par Receives FDA Approval to Market Generic Zofran ODT
November 29, 2005
Par Pharmaceutical's wholly owned subsidiary Kali Laboratories has received final FDA approval for its abbreviated new drug application (ANDA) for ondansetron HCl orally disintegrating tablets (ODT) in 4- and 8-mg dosage strengths.